BioNTech stock, a leader in messenger RNA technology and Pfizer's Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 which remained roughly flat over the same period. The stock also remains down by almost 55% from all-time highs seen in...
BioNTech stock, a leader in messenger RNA technology and Pfizer's Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 which remained roughly flat over the same period. The stock also remains down by almost 55% from all-time highs seen in...
Share this Article
Recommended